Email this article Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage
- Authors: Vorob'eva N.M.1, Panchenko E.P.1, Dobrovol'skiy A.B.1, Titaeva E.V.1, Khasaeva Z.B.1, Konovalova N.V.1, Postnov A.Y.1, Kirienko A.I.1, Vorobyeva NM2, Panchenko EP2, Dobrovolsky AB2, Titaeva EV2, Khasaeva ZB2, Konovalova NV2, Postnov AY.2, Kirienko AI3
-
Affiliations:
- Russian Cardiological Research Center
- N.I. Pirogov Second State Medical University, Moscow
- Issue: Vol 83, No 6 (2011)
- Pages: 59-65
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/30880
- ID: 30880
Cite item
Full Text
Abstract
Material and methods. The study included 111 patients with the history of deep vein thrombosis and/ or pulmonary artery thromboembolism. All the patients received non-fractionated or low-molecular heparin for at least 5 days, then warfarin (target INR 2.0-3.0). Warfarin dose was selected empirically. Gene CYP2C9 and VKORC1 polymorphisms were studied. HC were end points.
Results. Genotype CYP2C9*1/*1 (a "wild" type) was detected in 94 (84.7%) patients. Of other genotypes - heterozygotes CYP2C9*1/*2 (4.5%) and CYP2C9*1/*3 (10.8%). Genotyping by VKORC1 detected genotype GG (a wild type) in 42.3%, genotype GA - in 48.6%, genotype AA - in 9.1% patients. A mean warfarin dose, supporting an adequaite INR, was asspciated with both genotype CYP2C9 and VKORC1. Warfarin doses were highest in carriers of wile genotypes CYP2C9 and VKORC1 (6,9 and 8,8 mg/day), the lowest - in patients with genotypes CYP2C9*1/*3 and __ VKORC1 (4,5 and 4,0 mg/day). The carriers of polymorphisms CYP2C9*1/*3 and VKORC1 showed less stable anticoagulation vs carriers of allele variants CYP2C9*1/*1, CYP2C9*1/*2 and genotypes GG, GA VKORC1. An HC rate depended, as a rule, on carriage of genotypes CYP2C9*1/*3 and AA VKORC1. The highest risk of HC was associated with genotype CYP2C9*1/*3. The results of multifactorial regression analysis also indicated that carriage of genotype CYP2C9*1/*3, a female gender and the range of INR in warfarin treatment ≥ 2,66 are independent predictors of HC in VTEC patients on warfarin treatment.
Conclusion. Carriage of gene CYP2C9 and VKORC1 polymorphisms affects suppoting dose of warfarin and rate of hemorrhage in patients with VTEC in Moscow population. Frequency of HC is the highest in carriers of genotypes CYP2C9*1/*3 and AA VKORC1, they need minimal supporting dose of warfarin. Carriage of genotype CYP2C9*1/*3 in line with a female gender and instability of INR is an independent predictor of HC in VTEC patients in Moscow population on warfarin treatment.
About the authors
Natal'ya Mikhaylovna Vorob'eva
Email: natalyavorobjeva@mail.ru
Elizaveta Pavlovna Panchenko
Email: lizapanchenko@mail.ru
Anatoliy Borisovich Dobrovol'skiy
Email: abdobrovolsky@inbox.ru
Elena Vladimirovna Titaeva
Email: evlti@mail.ru
Zukhra Bilyalovna Khasaeva
Email: khasanova@mail.ru
Nina Valer'evna Konovalova
Email: miirka@mail.ru
Anton Yuvenal'evich Postnov
Email: anton-5@mail.ru
Aleksandr Ivanovich Kirienko
Email: phlebo-union@mtu-net.ru
N M Vorobyeva
Russian Cardiological Research CenterRussian Cardiological Research Center
E P Panchenko
Russian Cardiological Research CenterRussian Cardiological Research Center
A B Dobrovolsky
Russian Cardiological Research CenterRussian Cardiological Research Center
E V Titaeva
Russian Cardiological Research CenterRussian Cardiological Research Center
Z B Khasaeva
Russian Cardiological Research CenterRussian Cardiological Research Center
N V Konovalova
Russian Cardiological Research CenterRussian Cardiological Research Center
A Yu Postnov
Russian Cardiological Research CenterRussian Cardiological Research Center
A I Kirienko
N.I. Pirogov Second State Medical University, MoscowN.I. Pirogov Second State Medical University, Moscow
References
- Kearon C., Kahn S. R., Agnelli G. et al. Antithrombotic therapy for venous throm-boembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008; 133 (Suppl): 454S-545S.
- Guidelines on the diagnosis and management of acute pulmonary embolism. The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur. Heart J. 2008; 29: 2276-2315.
- Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. Флебология 2010; 1: 4-37.
- Кукес В. Г. Метаболизм лекарственных средств: клинико-фармакологические аспекты. М.: Реафарм; 2004.
- Rettie A. E., Jones J. P. Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annu. Rev. Pharmacol. Toxicol. 2005; 45: 477-494.
- Taube J., Halsall D., Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000; 96 (5): 1816-1819.
- Yin T., Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - Rationale and perspectives. Thromb. Res. 2007; 120 (1): 1-10.
- Сироткина О. В., Улитина А. С., Тараскина А. Е. и др. Аллельные варианты CYP2С9*2 и CYP2С9*3 гена цитохрома CYP2С9 в популяции Санкт-Петербурга и их клиническое значение при антикоагулянтной терапии варфарином. Рос. кардиол. журн. 2004; 6: 24-31.
- Moridani M., Fu L., Selby R. et al. Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort. Clin. Biochem. 2006; 39 (6): 606-612.
- Sconce E. A., Khan T. L., Wynne H. A. et al. The impact of CYP2C9 and VKORC1 polymorphism and patients characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106: 2329-2333.
- Ansell J., Hirsh J., Poller L. et al. The Pharmacology and Management of the Vitamin K Antagonists. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 204S-233S.
- Сычев Д. А., Стасяк Е. В., Игнатьев И. В. и др. Клиническая фармакогенетика изофермента цитохрома Р-450 2С9. Клин. фармакол. и тер. 2005; 4: 60-63.
- Gaikovitch E., Cascorbi L, Mrozikiewicz P. M. et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur. J. Clin. Pharmacol. 2003; 59: 303-312.
- Михеева Ю. А., Кропачева Е. С., Игнатьев И. В. и др. Полиморфизм гена цитохрома Р-450 2С9 (CYP2С9) и безопасность терапии варфарином. Кардиология 2008; 48 (3): 52-57.
- Панченко Е. П., Михеева Ю. А., Сычев Д. А. и др. Новый подход к повышению безопасности лечения варфарином (результаты фармакогенетического исследования). Кардиол. вестн. 2008; 2: 38-43.
- Sullivan P. W., Arant T. W., Ellis S. L., Ulrich H. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. Pharmacoeconomics 2006; 24 (10): 1021-1033.
- Sanderson S., Emery J., Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet. Med. 2005; 7 (2): 97-104.
- You J. H., Chan F. W., Wong R. S., Cheng G. The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy - a decision analysis. Thromb. Haemost. 2004; 92 (3): 590-597.
- Schulman S., Kearon C., Kakkar A. K. et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med. 2009; 361: 1-11.
- Agnelli G., Gallus A., Goldhaber S. Z. et al. Treatment of proximal deepvein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY59-7939): the ODIXa DVT (oral direct factor Xa inhibitor BAY59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation 2007; 116: 180-187.
- Buller H. R., Lensing A. W., Prins M. H. et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 2008; 112: 2242-2247.
Supplementary files
